Riskpilot← Back to searchSign inGet full accessOptoceutics ApS
APSActiveCVR 39769689Nørrebrogade 45C, 4. tvResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20186 employeeswww.optoceutics.com
Revenue 2024
DKK -519K
-157% vs 2023
EBITDA margin
1649.4%
-14% vs 2023
Equity ratio
74.0%
Financial strength
Net profit 2024
DKK -9,2M
-27% vs 2023
| Revenue | DKK -519K | -157% |
| EBITDA | DKK -8,6M | -14% |
| Net profit | DKK -9,2M | -27% |
| Total assets | DKK 46M | +13% |
| Equity | DKK 34,1M | +18% |
| Employees | 6 | — |
Legal name
Optoceutics ApS
CVR number
39769689
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
8. august 2018
Share capital
DKK 108.991
Employees
6 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør i forening med
bestyrelsens formand, af tre medlemmer af bestyrelsen i forening, eller af den
samlede bestyrelse
Company purpose
Selskabets formål er at drive kommerci-el virksomhed inden for højteknologiske produkter og serviceydelser baseret på lys-baserede produkter til kognitive for-bedringer og neurologisk behandling samt enhver aktivitet, der efter bestyrel-sens skøn står i forbindelse hermed
Address
Nørrebrogade 45C, 4. tv
Phone
+4523456442
Email
msc@optoceutics.com
Website
www.optoceutics.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | 889 | -132 | -2.177 | 4.263 | 910 | -519 |
| Staff expenses | -66 | -821 | -3.241 | -7.569 | -8.425 | -8.047 |
| EBITDA | 823 | -953 | -5.418 | -3.306 | -7.515 | -8.566 |
| Depreciation & amort. | -0 | -0 | -0 | -750 | -536 | -740 |
| EBIT | 823 | -953 | -5.418 | -4.056 | -8.051 | -9.306 |
| Net financials | -1 | -77 | -68 | -996 | -583 | -762 |
| Profit before tax | 822 | -1.030 | -5.486 | -5.052 | -8.633 | -10.068 |
| Tax | 170 | -523 | -1.606 | -1.416 | -1.422 | -884 |
| Net profit | 652 | -506 | -3.880 | -3.636 | -7.212 | -9.185 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 6.594 | 27.269 | 26.446 | 29.926 | 40.816 | 46.023 |
| Equity | 5.052 | 16.248 | 13.367 | 16.943 | 28.914 | 34.064 |
| Long-term debt | 0 | 8.746 | 8.500 | 9.472 | 10.059 | 9.861 |
| Short-term debt | 731 | 996 | 3.570 | 2.898 | 1.843 | 2.098 |
| Total debt | 731 | 9.741 | 12.070 | 12.370 | 11.901 | 11.959 |
EBITDA margin
-856597500.0%
This company
15.8%
Market median
-5421503265% vs market
20192024
Equity ratio
74.0%
This company
38.2%
Market median
+94% vs market
20192024
Return on equity
-27.0%
This company
18.4%
Market median
-247% vs market
20192024
Net profit margin
-918462500.0%
This company
8.1%
Market median
-11339043310% vs market
20192024
Asset turnover
-0.01×
This company
1.12×
Market median
-101% vs market
20192024
Debt / equity
0.35×
This company
0.62×
Market median
+44% vs market
20192024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2018-08-08 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
NM Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
MS Management | Management | 2019 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2019 | — | — | |
| Chairman | 2025 | — | — | |
| Chairman | 2019 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Danielsen 2 ApS | Company | 25.0% | 25.0% | 2022 |
| Individual | 15.0% | 15.0% | 2022 | |
M. S. C. HOLDING ApS | Company | 10.0% | 10.0% | 2024 |
Vjack Holding ApS | Company | 5.0% | 5.0% | 2020 |
| Individual | 5.0% | 5.0% | 2023 | |
BROENG CONSULT ApS | Company | 5.0% | 5.0% | 2018 |
CHRISTIAN NIELSENS FOND | Company | 5.0% | 5.0% | 2019 |
Lunox ApS | Company | 5.0% | 5.0% | 2018 |
LUCAS INNOVATION ApS | Company | 5.0% | 5.0% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Vjack Holding ApS
Optoceutics ApS Board members of Optoceutics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ngoc Mai Thi Nguyen | Chief Executive Officer | 0 companies |
| Marcus Schultz Carstensen | Management | 0 companies |
| Kaare Agerholm Danielsen | Board of Directors | 0 companies |
| David Lee Hardwick | Chairman | 0 companies |
| Vivienne L'Ecuyer Ming | Board of Directors | 0 companies |
| Jes Broeng | Chairman | 0 companies |
| Rasmus Just | Chairman | 0 companies |